ScoreWhy is Shield Therapeutics Plc ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -209.41% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -16.41
2
With a growth in Net Sales of 6.49%, the company declared Outstanding results in Dec 25
- The company has declared positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at GBP -13.38 MM
- NET SALES(Q) Highest at GBP 21.1 MM
- OPERATING PROFIT(Q) Highest at GBP -2.9 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 167.49%, its profits have risen by 37%
4
Market Beating Performance
- The stock has generated a return of 167.49% in the last 1 year, much higher than market (FTSE 100) returns of 17.87%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Shield Therapeutics Plc should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Shield Therapeutics Plc for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Shield Therapeutics Plc
167.49%
2.31
81.93%
FTSE 100
17.87%
1.52
11.77%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
29.36%
EBIT Growth (5y)
-209.41%
EBIT to Interest (avg)
-16.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-14.69
Sales to Capital Employed (avg)
1.03
Tax Ratio
2.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-6.20
EV to EBIT
-10.85
EV to EBITDA
-12.21
EV to Capital Employed
32.59
EV to Sales
2.21
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-300.29%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
OPERATING CASH FLOW(Y)
Highest at GBP -13.38 MM
NET SALES(Q)
Highest at GBP 21.1 MM
OPERATING PROFIT(Q)
Highest at GBP -2.9 MM
OPERATING PROFIT MARGIN(Q)
Highest at -13.76 %
PRE-TAX PROFIT(Q)
Highest at GBP -5.8 MM
NET PROFIT(Q)
Highest at GBP -6.06 MM
RAW MATERIAL COST(Y)
Fallen by -218.52% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 2.17 times
EPS(Q)
Highest at GBP -0.01
-3What is not working for the Company
INTEREST(HY)
At GBP 2.74 MM has Grown at 51.93%
INVENTORY TURNOVER RATIO(HY)
Lowest at 3.7 times
Here's what is working for Shield Therapeutics Plc
Net Sales
Highest at GBP 21.1 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (GBP MM)
Operating Profit
Highest at GBP -2.9 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (GBP MM)
Operating Profit Margin
Highest at -13.76 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at GBP -5.8 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (GBP MM)
Net Profit
Highest at GBP -6.06 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (GBP MM)
Operating Cash Flow
Highest at GBP -13.38 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (GBP MM)
Net Sales
At GBP 21.1 MM has Grown at 35.85%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (GBP MM)
EPS
Highest at GBP -0.01
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (GBP)
Debtors Turnover Ratio
Highest at 2.17 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -218.52% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Shield Therapeutics Plc
Interest
At GBP 2.74 MM has Grown at 51.93%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (GBP MM)
Inventory Turnover Ratio
Lowest at 3.7 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
